Patient and caregiver benefit‐risk preferences for nonmetastatic castration‐resistant prostate cancer treatment

BACKGROUND: Recently approved second‐generation androgen receptor inhibitors (SGARIs) for non‐metastatic castration‐resistant prostate cancer (nmCRPC) have similar efficacy but differ in safety profiles. We used a discrete choice experiment (DCE) to examine how nmCRPC patients and caregivers perceiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Srinivas, Sandy, Mohamed, Ateesha F., Appukkuttan, Sreevalsa, Botteman, Marc, Ng, Xinyi, Joshi, Namita, Tsai, Jui‐Hua, Fang, Jarjieh, Waldeck, A. Reginald, Simmons, Stacey J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520320/
https://www.ncbi.nlm.nih.gov/pubmed/32725755
http://dx.doi.org/10.1002/cam4.3321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520320/
https://www.ncbi.nlm.nih.gov/pubmed/32725755
http://dx.doi.org/10.1002/cam4.3321

Ejemplares similares